Streetbeat News

ATXI

Avenue Therapeutics, Inc.

https://www.avenuetx.com

Industry

Biotechnology

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Avenue Therapeutics (NASDAQ:ATXI) reported a Q2 EPS of $(6.43), significantly missing the analyst consensus estimate of $(1.05) by 512.38%. This represents an 83.4% improvement over the $(38.74) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:10 pm

Avenue Therapeutics has completed the last patient visit in its Phase 1b/2a clinical trial of AJ201 for Spinal and Bulbar Muscular Atrophy.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 12:32 pm

Avenue Therapeutics (NASDAQ:ATXI) reported a Q1 EPS of $(15.40), significantly missing the analyst consensus estimate of $(9.00) by 71.11%. This represents an 85.01% improvement over the $(102.75) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:49 pm

Avenue Therapeutics plans to potentially offer shares of common stock up to a total of $3.9M through an agent, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:56 pm

Clever Leaves Holdings Inc. announced its decision to voluntarily delist from Nasdaq, causing a 60% drop in its shares. Other stocks moved significantly in Monday's session, with Deciphera Pharmaceuticals surging 73% after an acquisition announcement, and various companies like Collective Audience and ImmunityBio also seeing substantial gains. Losers included Annovis Bio, down 57% after disappointing trial results, and Addex Therapeutics, falling 48.8% due to a failed epilepsy study.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 5:04 pm

Avenue Therapeutics (NASDAQ:ATXI) stock fell by 20.7% to $4.92 after announcing the exercise of warrants for $4.4 million in gross proceeds at a reduced price of $6.20 per share. The company will issue new Series C and D warrants as part of the transaction, expected to close by May 1, 2024. ATXI's stock has significantly declined over the past year, with a 93.29% decrease, and is currently considered oversold with an RSI of 27.91.

Portfolio Pulse from Henry Khederian

April 29, 2024 | 2:59 pm

Avenue Therapeutics' stock price has declined following the announcement of the exercise of warrants, resulting in $4.4 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:04 pm

Avenue Therapeutics announced the exercise of warrants resulting in $4.4 million in gross proceeds. This financial move could indicate a strengthening of the company's cash position, potentially impacting its operational capabilities and future investment opportunities.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:14 pm

Avenue Therapeutics' shares are trading lower following the announcement of a 1-for-75 reverse stock split of its common stock. This corporate action is typically undertaken by companies aiming to increase their share price by reducing the number of shares outstanding, which can have various implications for investors and the company's market perception.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 7:15 pm

Aon plc shares fell by 7.4% after reporting quarterly financial results below market expectations. Other stocks showed significant movement, with Biodexa Pharmaceuticals and Pineapple Energy among the top gainers, while iClick Interactive and Nuwellis were notable losers.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 5:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.